Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: Importance of patient's motivation and physician's treatment experience

Liver International

Volumn 29, Issue 5, 2009, Pages 721-729

  Tanioka, Daisuke ^a   Iwasaki, Yoshiaki ^a   Araki, Yasuyuki ^b   Osawa, Toshiya ^c   Ikeda, Hiroshi ^d   Ando, Masaharu ^e   Kobashi, Haruhiko ^a   Sakaguchi, Kohsaku ^f   Shiratori, Yasushi ^g   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b HIROSHIMA CITY HOSPITAL   (Japan)

^c OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^d KURASHIKI CENTRAL HOSPITAL   (Japan)

^e Mitoyo General Hospital   (Japan)

^f Fukuyama City Hospital   (Japan)

^g Miyamoto Hospital   (Japan)

Author keywords

Adherence; Retreatment; Treatment centre; Treatment experience

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL COMPETENCE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTIVATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; RETREATMENT; RISK FACTOR; SEX DIFFERENCE;

DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LOGISTIC MODELS; MALE; MIDDLE AGED; MOTIVATION; PATIENT ACCEPTANCE OF HEALTH CARE; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; RIBAVIRIN; STATISTICS, NONPARAMETRIC;

EID: 64749093949     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01964.x     Document Type: Article

References (28)

1. Hepatitis C-global prevalence. Wkly Epidemiol Rec 1999; 74: 425-7.
2. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
3. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
4. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-9.
5. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
6. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002; 123: 2082-99.
7. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.
8. Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. JAMA 2001; 285: 193-9.
9. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
10. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43: 54-63.
11. Tanaka Y, Hanada K, Mizokami M, et al. Inaugural article: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002; 99: 15584-9.
12. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73 (Part 3): 673-9.
13. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347-53.
14. Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo -Chiba Hepatitis Research Group. Gastroenterology 1997; 113: 558-66.
15. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-23.
16. Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials. Eurohep Study Group for viral hepatitis. Gastroenterology 1999; 117: 408-13.
17. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
18. Raptopoulou M, Tsantoulas D, Vafiadi I, et al. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. J Viral Hepat 2005; 12: 91-5.
19. McHutchison JG, Ware JE Jr, Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140-7.
20. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-81.
21. Ware JE Jr, Bayliss MS, Mannocchia M, et al. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30: 550-5.
22. Perrillo R, Rothstein KD, Rubin R, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004; 11: 157-65.
23. Castera L, Constant A, Henry C, et al. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther 2006; 24: 1223-30.
24. Cheng SJ, Bonis PA, Lau J, et al. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 231-40.
25. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002; 36: S128-34.
26. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711-9.
27. Strader DB. Understudied populations with hepatitis C. Hepatology 2002; 36: S226-36.
28. Gaeta GB, Precone DF, Felaco FM, et al. Premature discontinuation of interferon plus ribavirin for adverse effects: A multicentre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 1633-9.